Home › Free Stock Grades › RNA
Atrium Therapeutics, Inc. (RNA) Stock Grade
RNA · Healthcare
B-
Market Cap
$144.0M
P/E Ratio
—
Revenue Growth (YoY)
0.0%
Net Margin
-411.9%
Return on Equity
—
Dividend Yield
None
About Atrium Therapeutics, Inc.'s fundamentals
Atrium Therapeutics is a biotechnology company with a market capitalization of $144.0 million that reported zero year-over-year revenue growth, indicating no sales expansion in its latest period. The company posted a significant net loss, reflected in a net margin of -411.9%, meaning expenses substantially exceeded any revenue generated. The company does not pay a dividend, which is typical for early-stage biotech firms that typically reinvest capital into research and development.